Terlipressin
Also known as: Glypressin, Triglycyl-lysine vasopressin, Lucassin
Overview
Terlipressin is a synthetic vasopressin analog and prodrug designed for selective splanchnic vasoconstriction with reduced systemic vasopressor effects compared to vasopressin. FDA-approved in 2022 for hepatorenal syndrome type 1 (HRS-1) and widely used in Europe for esophageal variceal bleeding, terlipressin is cleaved in vivo to lysine-vasopressin, which acts on V1a receptors to produce prolonged, preferential splanchnic vasoconstriction. This reduces portal hypertension, limits variceal bleeding, and in HRS-1 improves renal perfusion by redirecting blood flow from the splanchnic circulation.
Mechanism of Action
Terlipressin is a prodrug metabolized by endopeptidases to lysine-vasopressin, which binds V1a receptors (vascular smooth muscle) with high affinity, stimulating Gq/11-phospholipase C-IP3-calcium signaling and strong vasoconstriction. Splanchnic arterioles are highly sensitive to V1a activation, resulting in splanchnic vasoconstriction that reduces portal venous inflow, lowers portal pressure, and compresses varices. This hemodynamic shift also redirects blood flow to the systemic circulation, improving renal perfusion in the setting of HRS-1 where renal vasoconstriction is triggered by splanchnic vasodilation.
Potential Benefits
- FDA-approved treatment for hepatorenal syndrome type 1
- Variceal bleeding control (EU approved)
- Selective splanchnic vasoconstriction reducing portal pressure
- Improved renal perfusion in HRS-1 (reduces need for dialysis)
- Longer duration of action than vasopressin (bolus dosing possible)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Hospital use only |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Up to 14 days (hepatorenal syndrome) |
FDA-approved (Terlivaz, 2022) for hepatorenal syndrome type 1. Also used in Europe/Asia for variceal bleeding.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intravenous Bolus 100%
Slow IV push every 6 hours. Hospital setting only.
Continuous Intravenous Infusion 100%
Alternative dosing protocol used in Europe.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Terlipressin:
Hepatorenal Syndrome Protocol
FDA-approved HRS-1 protocol — terlipressin + IV albumin.
Variceal Bleeding (ex-U.S.)
European acute variceal bleeding protocol — terlipressin + prophylactic antibiotics.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. Use reconstituted solution within 24 hours. |
|---|
Hospital pharmacy preparation.
Need exact syringe measurements?
Amino Acid Sequence
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (prodrug; cleaved to Lys-vasopressin)
Side Effects & Safety
- Hyponatremia
- Abdominal cramps and diarrhea
- Peripheral ischemia (skin, fingers) at high doses
- Hypertension
- Rare: mesenteric ischemia
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
FDA Safety Information
FDA Boxed Warning: Serious or fatal respiratory failure; also carries warnings for ischemic events and fluid overload.
Pharmacokinetics
| Half-Life | ~50 minutes (parent); active metabolite lysine-vasopressin ~6 hours |
|---|---|
| Storage | Refrigerate vials at 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside Terlipressin for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.